Total (n = 253) | 90-day return home (n = 94) | No 90-day return home (n = 159) | p | |
---|---|---|---|---|
Age, y | 65 [56–72] | 63 [54–69] | 65 [58–74] | 0.03 |
Male gender | 126 (49.8) | 33 (35.1) | 93 (58.5) | 0.001 |
Charlson Comorbidity Index | 10 [8–11] | 9 [8–10] | 10 [8–11] | 0.045 |
Performance Status 1 month before ICU admission | ||||
0–1 | 101 (40) | 52 (55) | 49 (32) | < 0.001 |
2–3–4 | 150 (59) | 41 (44) | 109 (71) | < 0.001 |
Malnutrition | 137 (54) | 33 (35) | 104 (65) | < 0.001 |
Albumin on day 1 | 28 [23–31] | 30 [24–32] | 27 [22–29] | 0.002 |
Primary tumour site | ||||
Lung, non-small cell | 82 (33) | 25 (27) | 57 (36) | 0.17 |
Breast | 41 (16) | 22 (24) | 19 (12) | 0.027 |
Colorectal | 23 (9) | 10 (10) | 13 (8) | 0.67 |
Kidney | 12 (5) | 2 (2) | 10 (6) | 0.23 |
Lung, small cell | 13 (5) | 6 (7) | 7 (4) | 0.69 |
Prostate | 10 (4) | 4 (4) | 6 (4) | 1.00 |
Stomach | 9 (4) | 2 (2) | 7 (4) | 0.55 |
Pancreas | 9 (4) | 5 (5) | 4 (3) | 0.42 |
Bladder | 9 (3) | 3 (3) | 6 (4) | 1.00 |
Hepatobiliary | 8 (3) | 0 (0) | 8 (5) | 0.30 |
Other | 37 (14) | |||
Metastatic site | ||||
Lung/pleura | 124 (49) | 48 (51) | 76 (50) | 1.00 |
Bone | 103 (41) | 38 (40) | 65 (41) | 1.00 |
Liver | 97 (38) | 32 (34) | 65 (41) | 0.34 |
Brain | 44 (17) | 18 (19) | 26 (16) | 0.69 |
Peritoneum | 39 (15) | 19 (20) | 20 (13) | 0.15 |
Adrenal gland | 28 (11) | 8 (9) | 20 (13) | 0.43 |
Other | 23 (9) | |||
Metastatic sites, n | 2 [1–3] | 2 [1–3] | 2 [1–3] | 0.39 |
LDH on day 1 (UI/L) | 321 [219–478] | 315 [190–434] | 329 [232–619] | 0.165 |
Antineoplastic therapy before ICU admission | ||||
Cytostatic chemotherapy | 148 (59) | 67 (71) | 81 (51) | 0.002 |
Endocrine therapy | 35 (14) | 16 (17) | 19 (12) | 0.35 |
Targeted therapy/immunotherapy | 89 (35) | 37 (40) | 52 (33) | 0.35 |
Radiotherapy | 70 (27) | 31 (33) | 39 (25) | 0.17 |
No previous treatment | 68 (27) | 13 (14) | 55 (35) | 0.001 |
Lines of antineoplastic therapy before admission, n | 2 [0–2] | 1 [1–3] | 1.00 [0–2] | < 0.001 |